• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Protara Therapeutics (TARA)

Common Shares
Sell: $5.34|Buy: $5.48|Change: 0.05 (0.94%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failureassociated liver disease (IFALD).

Address

1 Little West 12th Street
New York
NY
USA
10014

Telephone

+1 646 8440337

Website

https://www.protaratx.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Protara Therapeutics Inc Third Quarter Earnings Results for 20262026-11-10T00:00:00
Protara Therapeutics Inc Second Quarter Earnings Results for 20262026-08-11T00:00:00
Protara Therapeutics Inc Annual General Meeting for 20262026-06-11T12:00:00
Protara Therapeutics Inc First Quarter Earnings Results for 20262026-05-08T00:00:00
Protara Therapeutics Inc Fourth Quarter Earnings Results for 20252026-03-05T00:00:00
Protara Therapeutics Inc Annual Report for 20252026-03-05T00:00:00

Previous key dates

NameKey Date
Protara Therapeutics SUO Update Call2025-12-03T08:30:00
Protara Therapeutics Update Call2025-11-19T08:30:00
Protara Therapeutics Inc Third Quarter Earnings Results for 20252025-11-10T00:00:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-09T09:00:00
Cantor Global Healthcare Conference2025-09-04T13:35:00
Protara Therapeutics Inc Second Quarter Earnings Results for 20252025-08-11T00:00:00
Protara Therapeutics Inc Annual General Meeting for 20252025-06-11T12:00:00
TD Cowen 6th Annual Oncology Innovation Summit2025-05-27T13:30:00
H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference2025-05-20T12:30:00
Protara Therapeutics Inc First Quarter Earnings Results for 20252025-05-08T00:00:00
TD Cowen 45th Annual Health Care Conference2025-03-05T09:50:00
Protara Therapeutics Inc Fourth Quarter Earnings Results for 20242025-03-05T00:00:00
Protara Therapeutics Inc Annual Report for 20242025-03-05T00:00:00
Oppenheimer 35th Annual Healthcare Life Sciences Conference2025-02-12T12:40:00
43rd Annual J.P. Morgan Healthcare Conference2025-01-16T07:30:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.